Abeomics goal is to provide well-validated antibodies for different applications to research community.
As per discussions in the recently concluded seminar on Antibody Validation: Standards, Policies, and Practices at Asilomar, September 25, 2016-September 27, 2016, we are in the process of converting all our monoclonal antibodies produced by hybridoma technology to recombinant monoclonal antibodies to obtain consistence results and prevent lot-to-lot variations. The specificities of the antibodies will be validated either by siRNA or CRISPER/Cas9 tools.
